GlassScriptPhysician profile
Michael A Plastow
NPI 1366748873
$11,340.75
in general payments reported to CMS, 2019-2025
28 companies · $2,469 in 2025
The $2,469 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,151 · 2022: $2,302 · 2023: $2,047 · 2024: $2,371 · 2025: $2,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,831 · Education: $56.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,830.64 |
| Education | $56.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,816.78 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Csl Behring | $2,022.03 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $884.61 | 2021-2025 | Nucala |
| Genzyme Corporation | $777.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $554.09 | 2021-2025 | |
| Amgen INC. | $494.68 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $492.00 | 2021-2023 | Ruconest |
| Optinose US, INC. | $460.98 | 2021-2025 | |
| Grifols USA, LLC | $458.89 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $430.68 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Pfizer INC. | $386.58 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $378.48 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.60 | 2021-2023 | Spiriva Respimat |
| Genentech USA, INC. | $165.33 | 2021-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $128.31 | 2021-2023 | Cinqair |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $76.39 | 2022 | |
| Incyte Corporation | $75.43 | 2022-2025 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $69.09 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $54.79 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $52.52 | 2023-2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $48.58 | 2021-2023 | |
| Kaleo, INC. | $48.22 | 2021 | |
| Octapharma USA, INC. | $40.15 | 2023-2024 | Octagam Immune Globulin (Human), Cutaquig |
| Hikma Pharmaceuticals USA | $29.51 | 2023-2025 | Ryaltris |
| Lilly USA, LLC | $18.26 | 2025 | Ebglyss |
| Alk-Abello, INC | $16.08 | 2021 | |
| Horizon Therapeutics Plc | $15.22 | 2023 | Actimmune |
| Leo Pharma INC. | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Plastow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.